Ivermectin and cancer: company reports observational results

A company-affiliated observational analysis of 197 cancer patients reported an 84% clinical benefit ratio after six months of off‑label ivermectin plus mebendazole, and the authors call for formal clinical trials.

The Wellness Company published an article presenting an observational analysis of off‑label ivermectin plus mebendazole use in people with cancer. The piece is authored by Dr. Peter McCullough and colleagues and frames the work as a patient-focused response to declining trust in medical institutions. The article reports results from 197 patients who received a compounded oral formulation and were followed for six months. It also describes the company offering a compounded 90‑day supply and includes patient testimonials. Key findings: - The article reports an observational analysis of 197 cancer patients treated off‑label with compounded oral ivermectin (25 mg) plus mebendazole (250 mg) with six‑month follow‑up. - It reports an 84% clinical benefit ratio overall, with 48% described as reporting tumor regression or no evidence of disease, 36% reporting disease stability, and 15.6% reporting disease progression. - The article names Dr. Peter McCullough and colleagues as authors and quotes them urging a full‑fledged scientific investigation of the medication combination in cancer. - The Wellness Company is described as offering a compounded 90‑day supply of the combination and the article includes patient testimonials about individual experiences. Summary: The article reports an observational series claiming an 84% clinical benefit ratio in 197 patients treated with off‑label ivermectin plus mebendazole and quotes the authors calling for formal clinical trials. The company's availability of a compounded supply and included testimonials are noted as part of the report.